Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 [Yahoo! Finance]
Oncolytics Biotech Inc. - Common Shares (ONCY)
Last oncolytics biotech inc. - common shares earnings: 11/12 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.oncolyticsbiotech.com
Company Research
Source: Yahoo! Finance
Data from GOBLET in pancreatic and anal carcinoma support continued development of pelareorep in these indications, with combination studies ongoing Cash position of $15.9 million provides runway through critical milestones into third quarter 2025 Management hosting conference call and webcast this morning at 8:30 a.m. ET SAN DIEGO and CALGARY, AB March 7, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today reported on highlights and financial results for Q4 and year-end 2024. With its lead candidate, pelareorep, demonstrating strong efficacy signals in breast, pancreatic, and anal cancer, the company is strategically advanci
Read more
Impact Snapshot
Event Time:
ONCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ONCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ONCY alerts
High impacting Oncolytics Biotech Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
ONCY
News
- Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Maxim Group from $5.00 to $3.00. They now have a "buy" rating on the stock.MarketBeat
- Oncolytics Biotech Inc. (NASDAQ: ONCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Oncolytics Biotech Inc. (NASDAQ: ONCY) had its price target lowered by analysts at Royal Bank of Canada from $6.00 to $5.00. They now have an "outperform" rating on the stock.MarketBeat
- Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- https://seekingalpha.com/article/4765729-oncolytics-biotech-inc-oncy-q4-2024-earnings-call-transcript [Seeking Alpha]Seeking Alpha
ONCY
Earnings
- 3/7/25 - Miss
ONCY
Sec Filings
- 3/7/25 - Form 20-F
- 3/7/25 - Form 6-K
- 2/25/25 - Form 6-K
- ONCY's page on the SEC website